{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:40:06Z","timestamp":1777426806348,"version":"3.51.4"},"reference-count":49,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Pharmacokinetic differences between piperaquine (PQ) base and PQ tetraphosphate were investigated in 34 Papua New Guinean children aged 5 to 10 years treated for uncomplicated malaria with artemisinin-PQ (ART-PQ) base or dihydroartemisinin-PQ (DHA-PQ) tetraphosphate. Twelve children received ART-PQ base (two daily doses of 3 mg of ART and 18 mg of PQ base as granules\/kg of body weight) as recommended by the manufacturer, with regular clinical assessment and blood sampling over 56 days. PQ concentrations in plasma samples collected from 22 children of similar ages with malaria in a previously published pharmacokinetic study of DHA-PQ tetraphosphate (three daily doses of 2.5 mg of ART and 20 mg of PQ tetraphosphate as tablets\/kg of body weight) were available for comparison. The disposition of ART was also assessed in the 12 children who received ART-PQ base. Plasma PQ was assayed by high-performance liquid chromatography with UV detection, and ART was assayed using liquid chromatography-mass spectrometry. Multicompartment pharmacokinetic models for PQ and ART were developed using a population-based approach. ART-PQ base was well tolerated, and initial fever abatement and parasite clearance were prompt. There were no differences between the two treatments in the values for the PQ area under the concentration-time curve from time zero to infinity (AUC\n            <jats:sub>0\u2013\u221e<\/jats:sub>\n            ), with medians of 49,451 (\n            <jats:italic>n<\/jats:italic>\n            = 12) and 44,556 (\n            <jats:italic>n<\/jats:italic>\n            = 22) \u03bcg \u00b7 h\/liter for ART-PQ base and DHA-PQ tetraphosphate, respectively. Recurrent parasitemia was associated with lower PQ exposure. Using a two-compartment ART model, the median AUC\n            <jats:sub>0\u2013\u221e<\/jats:sub>\n            was 1,652 \u03bcg \u00b7 h\/liter. There was evidence of autoinduction of ART metabolism (relative bioavailability for the second dose, 0.27). These and previously published data suggest that a 3-day ART-PQ base regimen should be further evaluated, in line with World Health Organization recommendations for all artemisinin combination therapies.\n          <\/jats:p>","DOI":"10.1128\/aac.06232-11","type":"journal-article","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T04:58:03Z","timestamp":1333429083000},"page":"3288-3297","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacokinetic Comparison of Two Piperaquine-Containing Artemisinin Combination Therapies in Papua New Guinean Children with Uncomplicated Malaria"],"prefix":"10.1128","volume":"56","author":[{"given":"Sam","family":"Salman","sequence":"first","affiliation":[{"name":"School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhu","family":"Page-Sharp","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Curtin University of Technology, Bentley, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin T.","family":"Batty","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Curtin University of Technology, Bentley, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaye","family":"Kose","sequence":"additional","affiliation":[{"name":"Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Griffin","sequence":"additional","affiliation":[{"name":"Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Siba","sequence":"additional","affiliation":[{"name":"Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth F.","family":"Ilett","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Mueller","sequence":"additional","affiliation":[{"name":"Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M. E.","family":"Davis","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007310384"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.35116.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.25"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00279-11"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2006.01784.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/(SICI)1099-081X(199805)19:4<245::AID-BDD99>3.0.CO;2-Z","article-title":"Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses","volume":"19","author":"Ashton M","year":"1998","unstructured":"AshtonM. 1998. Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses. Biopharm. Drug Dispos. 19:245\u2013250.","journal-title":"Biopharm. Drug Dispos."},{"key":"e_1_3_2_8_2","first-page":"25","article-title":"Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults","volume":"26","author":"Ashton M","year":"1998","unstructured":"AshtonM. 1998. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab. Dispos. 26:25\u201327.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.08.016"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0378-4347(95)00428-9","article-title":"Selective high-performance liquid chromatographic determination of artesunate and alpha- and beta-dihydroartemisinin in patients with falciparum malaria. J. Chromatogr","volume":"677","author":"Batty KT","year":"1996","unstructured":"BattyKT. 1996. Selective high-performance liquid chromatographic determination of artesunate and alpha- and beta-dihydroartemisinin in patients with falciparum malaria. J. Chromatogr. B Biomed. Appl. 677:345\u2013350.","journal-title":"B Biomed. Appl."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4269\/ajtmh.1997.56.17","article-title":"Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers","volume":"56","author":"Benakis A","year":"1997","unstructured":"BenakisA ParisM LoutanL PlessasCT PlessasST. 1997. Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Am. J. Trop. Med. Hyg. 56:17\u201323.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000669"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4269\/ajtmh.1986.35.3","article-title":"The epidemiology of malaria in a population surrounding Madang, Papua New Guinea","volume":"35","author":"Cattani JA","year":"1986","unstructured":"CattaniJA. 1986. The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. Am. J. Trop. Med. Hyg. 35:3\u201315.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00927-08"},{"key":"e_1_3_2_16_2","volume-title":"Abstr. 18th Int. AIDS Soc. Conf., abstr THPE0158","author":"Crauwels HM","year":"2010","unstructured":"CrauwelsHM. 2010. Relative bioavailability of a concept paediatric formulation of TMC278, an investigational NNRTI. Abstr. 18th Int. AIDS Soc. Conf., abstr THPE0158."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/344647"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2003.69.558"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808859"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1994.51.785"},{"key":"e_1_3_2_21_2","unstructured":"European Medicines Agency. 2011. Eurartesim. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/001199\/WC500108010.pdf. Accessed September 1 2011."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000179"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1026-1031.2002"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02321.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02508.x"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2008.05.013"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0035-9203(96)90480-0","article-title":"Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients","volume":"90","author":"Hassan Alin M","year":"1996","unstructured":"Hassan AlinM AshtonM KihamiaCM MteyGJ BjorkmanA. 1996. Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans. R. Soc. Trop. Med. Hyg. 90:61\u201365.","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/512677"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02004.x"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00555-07"},{"key":"e_1_3_2_31_2","first-page":"971","article-title":"Dose ranging studies of new artemisinin-piperaquine fixed combinations compared to standard regimens of artemisisnin combination therapies for acute uncomplicated falciparum malaria","volume":"38","author":"Krudsood S","year":"2007","unstructured":"KrudsoodS. 2007. Dose ranging studies of new artemisinin-piperaquine fixed combinations compared to standard regimens of artemisisnin combination therapies for acute uncomplicated falciparum malaria. Southeast Asian J. Trop. Med. Public Health 38:971\u2013978.","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1248\/yakushi.127.1709","article-title":"Pharmacokinetics of piperaquine after single and multiple oral administrations in healthy volunteers","volume":"127","author":"Liu C","year":"2007","unstructured":"LiuC. 2007. Pharmacokinetics of piperaquine after single and multiple oral administrations in healthy volunteers. Yakugaku Zasshi 127:1709\u20131714.","journal-title":"Yakugaku Zasshi"},{"key":"e_1_3_2_33_2","first-page":"3019","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS. Anal","volume":"75","author":"Matuszewski BK","year":"2003","unstructured":"MatuszewskiBK ConstanzerML Chavez-EngCM. 2003. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS. Anal. Chem. 75:3019\u20133030.","journal-title":"Chem."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00679-09"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2008.79.620"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrd2197","article-title":"Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs","volume":"6","author":"Porter CJ","year":"2007","unstructured":"PorterCJ TrevaskisNL CharmanWN. 2007. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6:231\u2013248.","journal-title":"Nat. Rev. Drug Discov."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00486-07"},{"key":"e_1_3_2_38_2","first-page":"78","article-title":"Efficacy and safety of artemisinin-piperaquine (Artequick) compared to dihydroartemisinin-piperaquine (Artekin) in uncomplicated falciparum malaria in adults","volume":"21","author":"Pyar KP","year":"2009","unstructured":"PyarKP MyintWW KyawMP ZinT ThanM. 2009. Efficacy and safety of artemisinin-piperaquine (Artequick) compared to dihydroartemisinin-piperaquine (Artekin) in uncomplicated falciparum malaria in adults. Myanmar Health Sci. Res. J. 21:78\u201382.","journal-title":"Myanmar Health Sci. Res. J."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0084-9"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9066-0"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2125.1998.t01-1-00686.x","article-title":"Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria","volume":"45","author":"Sidhu JS","year":"1998","unstructured":"SidhuJS. 1998. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 45:347\u2013354.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2407-2411.2005"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0485-y"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0009-9236(98)90149-7","article-title":"Artemisinin induces omeprazole metabolism in human beings","volume":"64","author":"Svensson US","year":"1998","unstructured":"SvenssonUS. 1998. Artemisinin induces omeprazole metabolism in human beings. Clin. Pharmacol. Ther. 64:160\u2013167.","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00955-07"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5127-5128.2005"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11655-009-0189-6","article-title":"A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria","volume":"15","author":"Trung TN","year":"2009","unstructured":"TrungTN TanB Van PhucD SongJP. 2009. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. Chin. J. Integr. Med. 15:189\u2013192.","journal-title":"Chin. J. Integr. Med."},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(00)90300-6"},{"key":"e_1_3_2_49_2","volume-title":"Guidelines for the treatment of malaria\u2014","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. 2010. Guidelines for the treatment of malaria\u2014 2nd ed. World Health Organization, Geneva, Switzerland.","edition":"2"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006358"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.06232-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.06232-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:17:08Z","timestamp":1645481828000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.06232-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1128\/AAC.06232-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.06232-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"2011-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-05-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}